It is more frequently observed in patients with melanoma treated with anti-CTLA4 drugs (2–9%), anti-PD-L1 (7–11%), or combinations, while it is less frequent in patients treated with ICIs for other tumors. The gene discussed is CTLA4; the disease is melanoma.